Evaro Closes £18m Series A Led by AlbionVC to Scale Embedded Healthcare Infrastructure

January 26, 2026

Evaro, the NHS-licensed digital healthcare platform founded by emergency physician Dr Thuria Wenbar and pharmacist researcher Dr Oskar Wenbar, has closed a £18.3 million Series A funding round. The raise was led by AlbionVC, with participation from Simplyhealth Ventures, Exceptional Ventures, Cornerstone VC, and BBI. AlbionVC Partner Christoph Ruedig joins the board as part of the deal. The company has served more than two million patients to date and aims to reach ten million over the next three years.

Access to primary care in the UK is under mounting strain. More than 20.5 million people waited a month or longer for a GP appointment in 2024—a 60% increase over seven years. At the same time, a significant proportion of those appointments involve conditions that could be safely managed through digital channels. Evaro was founded to address this structural gap by building the regulatory and technical plumbing that makes embedded healthcare possible, rather than creating another patient-facing app competing with the NHS.

The platform provides regulated infrastructure—asynchronous consultations, remote diagnostics, prescribing, dispensing, and aftercare—that partner organisations can integrate within as little as two weeks without building clinical or pharmacy capabilities themselves. Evaro holds Care Quality Commission and General Pharmaceutical Council licences, seven active regulatory approvals, and NHS integration that enables GP record access for safer prescribing. Current partners include period-tracking app Clue, through which UK users can access NHS-funded contraception via Evaro's embedded pharmacy, and sexual wellness retailer Lovehoney. The platform supports more than 80 conditions and carries a 4.5 Trustpilot rating.

The Series A funding will support expansion into women's health, men's health, and longevity medicine, along with development of advanced diagnostics and aftercare capabilities. The company targets three distinct customer segments: consumer brands seeking new revenue streams, healthcare providers wanting to extend digital capacity for routine conditions, and employers deploying health benefits at scale.

AlbionVC's Christoph Ruedig drew an explicit parallel with embedded finance, describing Evaro as defining the equivalent category in healthcare. The backing from Simplyhealth Ventures—the investment arm of one of the UK's largest health cash plan providers—lends additional validation to the company's vision of embedding regulated care into brands that already hold consumer trust.

Sources